Incyte Europe — Total revenues increased by 21.6% to $92.43M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 34.7%, from $68.61M to $92.43M. Over 4 years (FY 2021 to FY 2025), Europe — Total revenues shows an upward trend with a 27.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful product adoption, expanded market share, or favorable pricing dynamics in Europe, while a decrease may signal competitive pressure or regulatory hurdles.
This metric represents the total gross revenue generated from the sale of pharmaceutical products and licensing arrangem...
Peers typically report this as 'Geographic Revenue' or 'Regional Net Sales', allowing for direct comparison of international market performance.
incy_segment_europe_total_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.03M | $31.03M | $31.03M | $36.75M | $36.75M | $36.75M | $36.75M | $43.97M | $43.97M | $43.97M | $43.97M | $51.50M | $53.59M | $66.46M | $88.86M | $68.61M | $78.83M | $100.31M | $75.99M | $92.43M |
| QoQ Change | — | +0.0% | +0.0% | +18.5% | +0.0% | +0.0% | +0.0% | +19.6% | +0.0% | +0.0% | +0.0% | +17.1% | +4.1% | +24.0% | +33.7% | -22.8% | +14.9% | +27.2% | -24.2% | +21.6% |
| YoY Change | — | — | — | — | +18.5% | +18.5% | +18.5% | +19.6% | +19.6% | +19.6% | +19.6% | +17.1% | +21.9% | +51.2% | +102.1% | +33.2% | +47.1% | +50.9% | -14.5% | +34.7% |